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Brain imaging with glucose (18F-FDG) PET or blood flow (hexame-
thylpropyleneamine oxime) SPECT is widely used for the differential
diagnosis of dementia, though direct comparisons to clearly estab-
lish superiority of one method have not been undertaken.Methods:
Subjects with Alzheimer disease (AD; n5 38) and dementia with Lewy
bodies (DLB; n 5 30) and controls (n 5 30) underwent 18F-FDG PET
and SPECT in balanced order. The main outcome measure was area
under the curve (AUC) of receiver-operating-characteristic analysis
of visual scan rating. Results: Consensus diagnosis with 18F-FDG
PET was superior to SPECT for both dementia vs. no-dementia
(AUC 5 0.93 vs. 0.72, P 5 0.001) and AD vs. DLB (AUC 5 0.80
vs. 0.58, P 5 0.005) comparisons. The sensitivity and specificity for
dementia/no-dementia was 85% and 90%, respectively, for 18F-
FDG PET and 71% and 70%, respectively, for SPECT. Conclusion:
18F-FDG PET was significantly superior to blood flow SPECT. We
recommend 18F-FDG PET be performed instead of perfusion SPECT
for the differential diagnosis of degenerative dementia if functional
imaging is indicated.
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Increasingly, dementia is an international governmental priority,
with early and accurate assessment and diagnosis placed at the
heart of effective management pathways. The 2 main causes of de-
generative dementia in older people are Alzheimer disease (AD),
responsible for about 65% of all cases, and dementia with Lewy
bodies (DLB), responsible for 10%–15% of cases. Most international
guidelines for the assessment and diagnosis of dementia advocate
the use of structural imaging, to exclude other intracerebral pa-
thologies and determine the extent of regional brain atrophy (1–3).
Functional imaging methods such as 18F-FDG PET and perfusion
(hexamethylpropyleneamine oxime [HMPAO]) SPECT are advo-
cated as useful to clarify diagnosis when doubt remains. Although
specific imaging ligands for amyloid are becoming available (4),
the mainstay of functional brain imaging for the differential diag-
nosis of dementia will remain 18F-FDG PETand blood flow SPECT
for the foreseeable future.
Abnormalities on 18F-FDG PET and perfusion SPECT in AD
are broadly similar with hypometabolism (for 18F-FDG PET) and
hypoperfusion (for SPECT) commonly affecting temporoparietal
areas in a bilateral distribution, with the posterior cingulate and
medial temporal areas particularly affected in AD and sensory
motor cortices, including the cerebellum, largely spared (5,6).
Changes in DLB overlap with the changes in AD, though more
profound parietooccipital hypometabolism and hypoperfusion is
seen in DLB (5,7).
SPECT and 18F-FDG PET differ in the equipment needed, im-
age characteristics, availability, and patient experience. 18F-FDG
PET allows brain metabolism to be directly assessed and offers
spatial resolution superior to SPECT (;5 vs.10 mm). HMPAO
SPECT measures brain perfusion captured around the time of in-
jection and so represents a slightly indirect measure of metabo-
lism. Despite the widespread clinical availability of both perfusion
SPECT and 18F-FDG PET, there remains uncertainty regarding
their relative diagnostic accuracy in a clinical setting. Studies of
the accuracy of SPECT for diagnosing AD report sensitivities of
65%–85% and specificities (for other dementias) of 72%–87% (8).
Studies for 18F-FDG PET generally report higher accuracy, with
sensitivities of 75%–99% for AD and specificities of 71%–93% (9).
However, there have been few direct head-to-head comparisons,
limited by small sample sizes and showing mixed results (10). For
example, although some studies have suggested slight superiority
of 18F-FDG PET for diagnostic accuracy, in the largest study to
date, both HMPAO SPECT and 18F-FDG PET were able to com-
pletely separate all 26 AD cases from controls (11). There has
been 1 small direct comparison study in DLB, finding that deficits
on 18F-FDG PET were greater than SPECT, though diagnostic
accuracy was similar (12). This uncertainty over the relative mer-
its of 18F-FDG PET and HMPAO SPECT is reflected in guidelines
for the use of imaging in the United Kingdom (2) and from the
European Federation of Neurologic Societies (1), which advocate
use of SPECT or 18F-FDG PET and consider both diagnostically
equivalent. Recently proposed diagnostic criteria for AD incorpo-
rate the use of biomarkers associated with neurodegeneration (1).
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In formulating these criteria there has been debate as to whether
perfusion SPECT is as acceptable a biomarker as 18F-FDG PET
(13,14).
Because of the increasing use of brain imaging investigations in
dementia with continuing uncertainty over the comparability of
18F-FDG PET and SPECT for diagnosis, we sought to undertake
a direct comparative study of the utility of perfusion (HMPAO)
SPECT and 18F-FDG PET for the differential diagnosis of degen-
erative dementia (AD and DLB) from similarly aged healthy con-
trols and also the subtype differentiation of AD from DLB.
Our hypothesis was that 18F-FDG PET would be significantly
superior to HMPAO SPECT.
MATERIALS AND METHODS
Subjects
Subjects were recruited prospectively from people aged over 60 y
with mild to moderate dementia (Mini-Mental Status Examination. 12)
referred to clinical services in North-East England together with
healthy controls of similar age. Subjects were recruited between June
2010 and June 2012. Control subjects had no symptoms of dementia,
and patients met criteria for probable AD (15) or probable DLB (16).
Clinical diagnosis was made by consensus between 2 experienced
clinicians. Neither 18F-FDG PET nor SPECT brain scans were used
to confirm the diagnosis. All subjects had to have sufficient command
of English and adequate visual and auditory acuity to allow cognitive
and neuropsychologic testing. Exclusion criteria were past history
of alcohol or drug dependence, contraindications for 18F-FDG PET
or SPECT scanning, or fasting blood glucose levels greater than
180 mg/dL. All subjects meeting inclusion and exclusion criteria who
consented were included in the study. We recruited 102 subjects, of whom
3 withdrew before completion and 1 was excluded because of scanner
technical problems. Thirty-eight AD subjects, 30 DLB subjects, and 30
controls were successfully scanned with both 18F-FDG PET and SPECT.
Subjects underwent detailed neuropsychiatric investigation includ-
ing the Cambridge Cognitive Examination (17), the Rey Auditory
Verbal Learning Test (18), and the trail-making test A&B (19). The
Cornell scale for depression in dementia (20) was used, and for de-
mentia participants we performed the Neuropsychiatric inventory (21)
and Clinician Assessment of Fluctuation (22). Parkinsonian motor
features were assessed using the motor subsection of the Unified
Parkinson Disease Rating Scale (UPDRS III) (23).
The study was approved by Newcastle and North Tyneside 1
Research Ethics Committee (REF 09/H0906/88), and all participants
(or nominated Independent Mental Capacity Advocate where partici-
pant lacked capacity) gave informed consent before participating. The
study is registered on the ISRCTN register, number ISRCTN49486383.
Scanning
The order of each scan (18F-FDG PET/SPECT) alternated between
consecutive subjects within each group. SPECT head scans were acquired
using a Siemens Symbia S dual-detector g camera, starting 30 min
after the intravenous administration of 500 MBq of 99mTc-HMPAO.
One hundred twenty 25-s planar views were obtained on a 128 · 128
matrix, zoom 1.23 (pixel size, 3.9 mm), using a low-energy high-
resolution collimator and circular orbit with a typical radius of
14 cm. Section images were produced with Hybrid Recon Neurology
software (Hermes Medical Solution Ltd.) using ordered-subset expec-
tation maximization iterative reconstruction with 4 iterations and 20
subsets, postfiltered with a 3-dimensional gaussian filter of 1.1 cm in
full width at half maximum with uniform attenuation correction and
resolution recovery. 18F-FDG PET head scans were obtained over
10 min using a Siemens Biograph Truepoint 18F-FDG PET/CT scan-
ner starting 30 min after intravenous administration of 250 MBq of
18F-FDG. Siemens software was used for iterative reconstruction with
scatter and attenuation correction based on the CT scan data obtained
immediately before the 18F-FDG PET scan. In both PET and SPECT,
patients were injected in quiet surroundings with minimal distractions
and eyes open.
Visual Rating
The primary outcome preselected for the study was diagnostic
accuracy using visual scan assessment. Scans were rated visually by 3
medical physicists who were unaware of the diagnosis and any clinical
information. Two of the physicists were clinical scientists who, after
appropriate training by nuclear medicine physicians, were fully ap-
proved by their National Health Service (NHS) employer for diagnostic
reporting of scans and both had more than 20 y of experience in
undertaking diagnostic brain scan reporting in dementia within the
NHS. The third physicist had 10 y of research experience in
neuroimaging analysis in dementia. Separate identification labels were
randomly generated for the 18F-FDG PET and SPECT scans, so it was
not possible for the readers to compare the 18F-FDG PET scan for an
individual with the matching SPECT scan. For visual rating, for both
PET and SPECT, the observers viewed a display with 15 axial, coronal,
and sagittal slices covering the whole brain, 128 · 128 pixels each slice.
PET and SPECT scans were both oriented to the orbitomeatal line.
In the visual rating, the key imaging features were reduced uptake
in the precuneus and lateral parietal lobes in both AD and DLB,
relative preservation of posterior cingulate in DLB, more extensive
occipital loss in DLB, and that reduced uptake in temporal and frontal
lobe is more likely in AD.
Each reader independently rated each scan on a 5-point scale for the
degree of confidence in overall abnormality typical of dementia. For
all scan findings not considered to be definitely normal, the match to
AD or DLB was also rated, again using a 5-point scale. After
individual ratings were completed, the imaging team met to compare
and review all their ratings and to produce a set of consensus ratings
for each scan. Each scan result was also given a tripartite consensus
classification of normal, AD, or DLB.
Quantitative Analysis
Quantitative analysis was a secondary outcome. To create study-
and modality-specific templates, each SPECT scan was spatially
coregistered with the same subject’s 18F-FDG PET scan. The 18F-FDG
PET scans were then spatially aligned (rigid body 9 degrees of freedom)
to the standard template in SPM8 (www.fil.ion.ucl.ac.uk/spm), with the
same alignment parameters being applied to the SPECT scans. Sepa-
rate study-specific templates for SPECT and 18F-FDG PET were then
created by averaging the aligned scans. The original scans were then
nonlinearly spatially normalized to the relevant template. Registration
accuracy was visually checked at each stage. Mean intensity within
standard regions of interest (ROIs) were then calculated for each scan.
ROIs were taken from the AAL atlas (24) for medial temporal lobe
(MTL) (hippocampus 1 parahippocampus gyrus), medial occipital
lobe (calcarine 1 lingual gyrus), lateral occipital (occipital_inf 1
occipital_med) (inf and med are inferior and medial, respectively), and
parietal lobe (angular gyrus). Also, ROIs for the cerebellum, precuneus,
and posterior cingulate were manually drawn on the study-specific
template. One subject was excluded from this analysis because the
cerebellum was not covered on the SPECT scan. Voxel-level comparison
between groups for both SPECT and 18F-FDG PET was also performed
in SPM8 using the mean cerebellum intensity to scale the images.
Statistics
Demographic and clinical rating data were analyzed with SPSS
19.0 (IBM). Continuous variables were compared using independent
Student t tests or ANOVA. x2 tests were used to compare categoric
data.
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Receiver-operating-characteristic (ROC) analysis was performed
using Metz software (http://metz-roc.uchicago.edu/MetzROC/software).
ROC analysis looks at the relationship between sensitivity and spec-
ificity dependant on the diagnostic cutoff on the visual rating or test
score. ROC curves were calculated for each rater individually, the
multireader case by combining data from all 3 raters, and also from
the consensus rating agreed on by the raters after individual rating was
done. We compared area under the curve (AUC) for 18F-FDG PET
versus SPECT using both the original visual ratings from all observers
(with the multiple readers and multiple cases package (25)) and the
consensus rating using the ROCKIT package (Metz Software). We
also analyzed the ROI quantitative data using ROCKIT.
RESULTS
Demographics
SPECTand 18F-FDG PET/CT scans were
obtained within 4 mo of recruitment, with
a mean time between scans of 11 d (SD,
12.6; maximum, 89 d). There were no ad-
verse events during any scans. As Table 1
shows, the groups were well matched for
age, sex, and duration of dementia. There
were no significant differences between AD
and DLB in Cambridge Cognitive Exami-
nation score. As expected, the DLB group
had significantly higher scores on the Uni-
fied Parkinson Disease Rating Scale, whereas
the AD group had poorer memory perfor-
mance on the Rey Auditory Verbal Learn-
ing Test. Figure 1 shows examples of char-
acteristic control, AD, and DLB 18F-FDG
PET and SPECT scans, demonstrating the
superior spatial resolution of 18F-FDG PET.
Visual Rating
Table 2 summarizes the ROC analysis
for the distinction of dementia (AD and
DLB) from healthy control. For all readers
TABLE 1
Subject Demographics
Parameter Control (n 5 30) AD (n 5 38) DLB (n 5 30) Test
Age (y) 76.3 ± 6.6 75.8 ± 7.5 76.5 ± 5.8 F2,95 5 0.09, P 5 0.9
Education (y) 11.9 ± 2.8 11.5 ± 2.6 10.6 ± 2.3 F2,95 5 1.91, P 5 0.15
Sex χ2 5 2.6, P 5 0.27
Female 10 16 7
Male 20 22 23
Duration of dementia (mo) — 44.0 ± 22.9 (12–132) 38.1 ± 27.3 (9–120) t66 5 0.99, P 5 0.3*
Mini-Mental Status Examination 28.9 ± 1.1 (26–30) 20.9 ± 3.7 (15–28) 21.8 ± 4.2 (14–28) t66 5 −1.0, P 5 0.3*
Cambridge Cognitive Examination 98.4 ± 4.0 71.3 ± 11.6 72.6 ± 13.1 t66 5 −0.43, P 5 0.7*
Rey total 70.3 ± 12.3 25.6 ± 10.0 33.4 ± 12.1 t66 5 −2.9, P 5 0.005*
Cornell 1.8 ± 1.8 4.5 ± 2.7 8.1 ± 3.8 F2,95 5 36.2, P , 0.001
Clinician Assessment of Fluctuation
scale total
— 1.5 ± 2.5 6.0 ± 4.7 t65 5 −4.7, P , 0.001*
Neuropsychiatric Index total — 15.6 ± 15.4 19.7 ± 15.6 t65 5 −1.1, P 5 0.3*
UPDRS† 2.6 ± 2.7 3.6 ± 3.2 25.5 ± 11.9 F2,95 5 105, P , 0.001
*AD vs. DLB Student t test.
†Motor part of UPDRS.
Values are mean ± SD, with range in parentheses. ANOVA Tukey post hoc tests: UPDRS5 control vs. AD post hoc P 5 0.8, DLB . AD
and DLB . control P , 0.001. Cornell 5 control , AD , DLB P 5 0.001. There were data only for 29 DLB for Clinician Assessment of
Fluctuation scale and Neuropsychiatric Index scores.
FIGURE 1. Example of 18F-FDG PET and SPECT scans for AD, DLB, and control. Medial
temporal loss in AD (arrow) and occipital lobe reduction (asterisk) and posterior cingulate island
sign (arrowhead) in DLB are shown.
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individually (Supplemental Table 1; supplemental methods are
available at http://jnm.snmjournals.org), the multireader, and the
consensus analysis, the AUC for 18F-FDG PET was significantly
greater than SPECT. For diagnosing AD versus DLB, with both
the consensus visual rating (Table 3) and the multireader analysis
(Supplemental Table 2), 18F-FDG PET had a significantly larger
AUC than SPECT, indicating better diagnostic performance for
18F-FDG PET. There was little variation in diagnostic accuracy
between raters, though in the distinction between AD and DLB
(Supplemental Table 2) there was a slightly wider variation in di-
agnostic accuracy between raters for SPECT (0.516–0.660) than for
PET (0.693–0.775).
Although the AUC was the primary outcome measure of the
study, we also calculated estimates of the specificity and sensitivity
using the consensus classification.
Table 4, Supplemental Table 3, and Figure 2 (flowchart) show
the comparison of the consensus tripartite diagnosis versus actual
diagnosis and accuracy of PET versus SPECT. There was a partic-
ular tendency on SPECT to categorize AD as normal.
For the decision of dementia versus healthy, when the consensus
diagnosis was used 18F-FDG PET had a sensitivity of 0.85 (95%
confidence interval [CI], 0.75–0.93) and a specificity of 0.90 (95%
CI, 0.73–0.98), whereas SPECT had sensitivity of 0.71 (95% CI,
0.58–0.81) and specificity of 0.70 (95% CI, 0.51–0.85). For AD
versus DLB, taking those with a correct imaging diagnosis of
dementia (fifty-eight 18F-FDG PET and 48 SPECT), 18F-FDG
PET sensitivity for AD was 0.74 (95% CI, 0.57–0.88) and spec-
ificity was 0.70 (95% CI, 0.47–0.87) whereas for SPECT, sensi-
tivity for AD was 0.54 (95% CI, 0.33–0.74) and specificity 0.67
(95% CI, 0.45–0.84). Supplemental Tables 4 and 5 show the cross
tabulation of the visual rating for 18F-FDG PET versus SPECT.
There was a tendency for scan results correctly classified as de-
mentia on 18F-FDG PET to be called normal on SPECT, and
SPECT seemed to have better performance for DLB, with most
AD SPECT scans being rated unclear.
Quantitative Scan Analysis
Figure 3 shows the results of the voxelwise SPM analysis. Both
modalities show broadly similar patterns, with reductions in the
parietal and temporal lobes in dementia, with AD having reduced
MTL uptake and DLB-reduced uptake in the occipital lobe. As
Figure 3 and Supplemental Table 6 show, the reductions were
more significant using 18F-FDG PET than SPECT, particularly
for dementia, compared with control. Supplemental Table 7 shows
the number of significant voxels at different threshold values, and
in all comparisons, 18F-FDG PET has at least 3 times as many
significant voxels as SPECT. We also repeated the analysis with
intensity normalization to the pre- 1 postcentral gyrus region, and
this produced similar findings.
The cingulate island sign in DLB (26) of preserved posterior
cingulate activity relative to the precuneus was seen in 18F-FDG
PET but not SPECT imaging (Fig. 1; Supplemental Table 6). In
keeping with previous research (27,28), the most significant differ-
ences in the ROI analysis between control and the combined AD
and DLB group were in the parietal-to-cerebellum ratio and for
AD versus DLB, the ratio of medial occipital to MTL (Supple-
mental Table 6). We therefore examined the relative diagnostic
performance of 18F-FDG PET versus SPECT with these ratios
using ROC analysis (Tables 2 and 3).
For the distinction of control versus dementia (AD and DLB),
the AUC for the quantitative parietal and cerebellum ROI mea-
surement gave a performance similar to the visual rating and
demonstrated the superior diagnostic ability of 18F-FDG PET. For
differentiating AD from DLB using the ROI measure of medial
occipital and MTL, the AUC for 18F-FDG PET was greater than
SPECT, although this was not significant.
DISCUSSION
Our main findings showed the significant superiority of 18F-
FDG PET over HMPAO SPECT in the differentiation of degener-
ative dementia (AD and DLB combined) from healthy controls
TABLE 2
ROC Analysis for 18F-FDG PET Versus SPECT in Healthy Versus Dementia
18F-FDG PET vs. SPECT
Assessment 18F-FDG PET AUC ± SE SPECT AUC ± SE AUC difference 95% CI P
Consensus rating 0.929 ± 0.028 0.722 ± 0.058 0.208 0.102–0.313 A 5 3.85, P 5 0.001
ROI parietal/cerebellum 0.940 ± 0.023 0.727 ± 0.054 0.214 0.124–0.303 A 5 4.67, P , 0.001
A 5 correlated AUC test statistic.
TABLE 3
ROC Analysis for 18F-FDG PET Versus SPECT in AD Versus DLB
18F-FDG PET vs. SPECT
Assessment 18F-FDG PET AUC ± SE SPECT AUC ± SE AUC difference 95% CI P
Consensus rating 0.799 ± 0.059 0.578 ± 0.074 0.221 0.096–0.346 A 5 3.47, P 5 0.005
ROI medial occipital/MTL 0.855 ± 0.055 0.787 ± 0.058 0.068 −0.016–0.152 A 5 1.58, P 5 0.11
A 5 correlated AUC test statistic.
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and for the differentiation of AD from DLB. The superiority of
18F-FDG PET was consistently demonstrated across all 3 of our
prespecified methods of analysis. On the primary outcome, the
clinically relevant endpoint of visual diagnostic read, 18F-FDG
PET had a sensitivity of 85% and specificity of 90% for distin-
guishing dementia versus no-dementia whereas SPECT had a sen-
sitivity of 71% and specificity of 70%. The high diagnostic accu-
racy of 18F-FDG PET is consistent with previous literature (9),
demonstrating that it is a robust marker for assessing neurodegen-
eration in both AD and DLB. Our findings therefore strongly
support its incorporation in imaging diagnostic guidelines and as
a biomarker of degeneration in newly proposed diagnostic criteria
for AD. In contrast, the diagnostic accuracy of perfusion SPECT
was significantly poorer. Although for the dementia/no-dementia
comparison diagnostic accuracy might still be clinically helpful,
accuracy for differentiating AD from DLB was disappointingly
poor and not at a level where it is likely to be clinically useful.
Although spatial resolution is higher in 18F-FDG PET, and im-
proves visual appearance, this is unlikely to have been the only
cause of the diagnostic accuracy difference, because the ROI re-
sults (which are from the mean value of regions encompassing
several cubic centimeters) also demonstrated the superior accuracy
of 18F-FDG PET.
There are clearly other considerations apart from diagnostic ac-
curacy when deciding on which imaging tests to undertake. SPECT
has been advocated over 18F-FDG PET on the basis of its wider
availability, lower cost, and perceived better patient tolerability.
However, with the widespread use of 18F-FDG PET for oncology
(responsible for more than 90% of 18F-FDG PET scans undertaken
worldwide), costs of 18F-FDG PET have reduced considerably. For
example, the price of 1 patient dose of 18F-FDG has halved in the
last decade, to under £200 (;US$300), comparable to the price of
HMPAO. Also, PET/CT scanners are now widely available, so
availability of scanners should no longer be a deterrent to its use.
Strengths of our study are the inclusion
of representative subjects presenting to
clinical services with AD and DLB, rather
than selected samples from specialist clinics.
We undertook both SPECT and 18F-FDG
PET scans in balanced order within a short
time frame. Our primary visual analysis was
validated by ROI and voxel-based ap-
proaches, which are less operator-dependant.
Both these methods demonstrated that dif-
ferences on 18F-FDG PET were both more
widespread and of greater significance than
SPECT. For example, SPECT showed 7%
of voxels in those with dementia that were
statistically significantly different from con-
trols, compared with 40% for 18F-FDG PET.
Our study used a clinical diagnostic
standard of consensus clinical diagnosis.
Although a clinical diagnostic standard can
always be criticized in the absence of
autopsy, this approach has been validated
in our group against both autopsy and other
imaging markers and is a standard now
accepted by regulatory authorities (29). It
is highly unlikely that clinical misdiagno-
sis could have accounted for our findings
of the superiority of 18F-FDG PET over
SPECT. To invoke this interpretation, one
would have to assume that many of our
subjects with established dementia were
actually healthy controls. Our findings of
perfusion SPECT being of limited diagnos-
tic utility for differentiating DLB from
AD are in agreement with previous studies
(30). This is in contrast to dopaminergic
SPECT, which is widely used for differen-
tiating DLB from AD and would be the bio-
marker of choice in this particular clinical
TABLE 4





Normal AD DLB Normal AD DLB
Control 27 1 2 21 0 9
AD 3 26 9 14 13 11
DLB 7 7 16 6 8 16
FIGURE 2. Flowchart of patients in study. 18F-FDG PET and SPECT diagnoses are from con-
sensus tripartite decision.
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situation (31). However, because HMPAO SPECT and 18F-FDG PET
are widely used in the initial evaluation of degenerative dementia
when there is diagnostic uncertainty, it is clinically relevant to know
their relative diagnostic accuracy for distinguishing DLB from AD,
thus indicating whether or not an additional dopaminergic scan is
likely to be informative, which our study suggests it would be.
Our study did not compare 18F-FDG PET and perfusion SPECT
against other dementia biomarkers such as cerebrospinal fluid,
amyloid imaging, or, for DLB, dopaminergic imaging of the basal
ganglia. This was not the aim of the study, because these other
biomarkers have previously been assessed (4), but more important,
18F-FDG PET and perfusion SPECT are the imaging tools most
likely to be requested first before more specific biomarker studies.
CONCLUSION
We undertook a direct comparison of the diagnostic value of
18F-FDG PET and perfusion (HMPAO) SPECT in the differential
diagnosis of degenerative dementia and found 18F-FDG PET to be
significantly superior to SPECT using all methods of analysis. The
performance of SPECT was such that it is
of only limited diagnostic value. Although
we can envisage circumstances when HMPAO
SPECT may still be a useful investigation,
in most circumstances and especially when
both 18F-FDG PET and perfusion SPECT are
available, our results strongly indicate that
18F-FDG PET should be the clinical investi-
gation of choice for the differential diagno-
sis of degenerative dementia. We recommend
that national and international guidelines are
updated to reflect this new evidence.
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FIGURE 3. SPM results, voxelwise threshold P 5 0.0005, uncorrected for multiple compari-
sons. Top row shows reduction in all dementia vs. control. Bottom row shows reductions of
AD vs. DLB (in blue) and reductions in DLB vs. AD (in red/yellow).
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